

Aculabs, Inc.
2 Kennedy Boulevard
East Brunswick, NJ 08816

T: 732.777.2588
855.ACU.LABS
F: 732.777.2640
www.aculabs.com



To: All Applicable Parties
Date: May 29th, 2020
Re: Update on Aculabs Employee Testing for COVID-19

As the COVID-19 pandemic remains ongoing, Aculabs has taken all necessary steps to remain in compliance with all federal and state-level safety and health regulations. This includes those set forth by both Gov. Phil Murphy via executive order and through bodies of the State of New Jersey, including but not limited to the New Jersey Department of Health.

This memorandum is meant to address the necessary steps Aculabs will continue to take to ensure our operations prioritize both the safety of all residents within the the post-acute care facilities we service and of our dedicated employees.

Upon the May 12th, 2020 release of **Executive Directive 20-013** by Judith Persichilli, Commissioner of Health, New Jersey, Aculabs began immediately arranging for all of its employees with direct patient contact to undergo the SARS-CoV-2 molecular testing via RT-PCR for COVID-19.

Aculabs will follow the below guidance set forth by the New Jersey Department of Health for testing healthcare personnel (“HCP”) for COVID-19 when rolling out employee testing:

- **Asymptomatic HCP Tested Positive** -Time-based strategy: Asymptomatic HCP who have tested positive for COVID-19 may return to work 10 days after their first positive COVID-19 test AND have had no subsequent symptoms. If symptoms develop, refer to the “Symptomatic HCP Tested Positive” criteria, below.
- **Symptomatic HCP Tested Positive** - Symptom-based strategy: 10 days after symptoms first developed AND 3 days (72 hours) after fever has resolved without the use of fever-reducing medications with a significant improvement in respiratory symptoms (whichever period is longer).

Employees who test negative and are asymptomatic will be instructed to return to work and mandated to follow all current guidance to reduce the risk of exposure and transmission of COVID-19, including but not limited to company policy on personal protective equipment.

Aculabs will also incorporate the usage of both molecular and antibody SARS-CoV-2 testing to ensure compliance with the following guidance set forth by the Center for Disease Control:

Access to Adequate Testing: The capacity for all nursing home staff (including volunteers and vendors who are in the facility on a weekly basis) to receive a single baseline COVID-19 test, with re-testing of all staff continuing every week (note: State and local leaders may adjust the requirement for weekly testing of staff based on data about the circulation of the virus in their community).

To comply with the standard set forth by the CDC, Aculabs will ensure each employee with direct patient contact undergoes baseline COVID-19 testing. Those with positive results will follow the above guidance via the NJ Department of Health and return to work once clearing the outlined criteria. Employees who have never tested positive will undergo baseline testing with a weekly retesting until further notice or until the guidance is lifted.

Aculabs will continue to meet all safety and health standards put forward during the pandemic.

Sincerely,

Peter Gudaitis
President